ArticleNan fang yi ke da xue xue bao = Journal of Southern Medical University2020
[Effects of artesunate on eosinophil apoptosis and expressions of Fas and Bcl-2 proteins in asthmatic mice].
Article in Nan fang yi ke da xue xue bao = Journal of Southern Medical University, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 8 citations in OpenAlex.
- Targeting of MAPK-ERK1/2 signaling by metformin in asthma: an updated mechanistic insight.Naunyn-Schmiedeberg's archives of pharmacology · 2026Review
- Efficacy of artesunate in asthma: based on network pharmacology and molecular docking.Journal of thoracic disease · 2023Article
- Artesunate inhibits airway remodeling in asthmaFrontiers in pharmacology · 2023Article
- Research progress of serum eosinophil in chronic obstructive pulmonary disease and asthma.Open life sciences · 2023Review
- New Insights into Artesunate as a Pleiotropic Regulator of Innate and Adaptive Immune Cells.Journal of immunology research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo observe the effects of artesunate on eosinophil (EOS) apoptosis and Fas and Bcl-2 protein expressions in asthmatic mice.
methodsThirty female BALB/c mice aged 6-8 weeks were randomly divided into control group, asthma group and artesunate group. Except for those in the control group, all the mice were sensitized with aerosolized ovalbumin to establish mouse models of asthma. In artesunate group, the rats were intraperitoneally injected with artesunate 1 h before ovalbumin inhalation from the 21st day of modeling. The lung tissues were harvested for staining 24 h after the last challenge. Flow cytometry was used to analyze the percentage and apoptosis rate of EOS in the alveolar lavage fluid (BALF). The apoptosis of EOS in the lung tissue was detected with TUNEL method, and Fas and Bcl-2 protein expressions were detected using immunohistochemistry.
resultsCompared with those in asthma group, the artesunate-treated mice had significantly decreased percentage of EOS in the BALF (
conclusionsArtesunate regulates the protein expressions of Fas and Bcl-2 to reduce EOS infiltration in the lung tissue and promote EOS apoptosis in asthmatic mice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.